{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:19:45Z","timestamp":1790363985771,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology","award":["JP 16K10514"],"award-info":[{"award-number":["JP 16K10514"]}]},{"name":"JKA Foundation through its promotion funds from the Keirin Race","award":["27-1-068 (2)"],"award-info":[{"award-number":["27-1-068 (2)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>HER2-targeted therapies have improved outcomes in metastatic gastric cancer (mGC), yet assessment of HER2 status in tumor tissues remains limited by heterogeneity and temporal changes. This study aimed to evaluate real-time HER2 expression on circulating tumor cells (CTCs) using the On-chip Sort system. CTCs were enriched from blood samples of 27 mGC patients, identified by cytokeratin staining, and assessed for HER2 expression via fluorescent labeling. The epithelial-mesenchymal transition (EMT) index was calculated based on co-expression of vimentin and cytokeratin. CTCs also underwent whole-genome amplification and targeted sequencing using a cancer gene panel. Patients were stratified into three groups: Group A (<jats:italic>n<\/jats:italic>\u2009=\u200913), HER2-positive in tissue; Group B (<jats:italic>n<\/jats:italic>\u2009=\u20098), tissue HER2-negative but CTC HER2-positive; and Group C (<jats:italic>n<\/jats:italic>\u2009=\u20096), HER2-negative in both tissue and CTCs. All patients received cytotoxic chemotherapy; only Group A received additional HER2-targeted therapy. Group B showed the poorest progression-free survival (PFS: 7.0 months), compared to Group A (15.7 months) and Group C (not reached). CTC HER2 expression correlated with EMT index; Groups A and B also exhibited higher EMT indices and shared EMT-related mutations. These findings suggest that CTC-based HER2 monitoring reflects tumor aggressiveness and may help identify patients who could benefit from HER2-targeted therapy despite negative tissue HER2 status.<\/jats:p>","DOI":"10.1038\/s41598-025-06913-x","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:05:00Z","timestamp":1751619900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-time assessment of circulating tumor cells refines the indication for HER2-targeted therapy in metastatic gastric cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Yasuaki","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-0628","authenticated-orcid":false,"given":"Koichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iku","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Ichida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Rikiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"6913_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani, J. A. et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 20, 167\u2013192 (2022).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"6913_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 144, 1941\u20131953 (2019).","journal-title":"Int. J. Cancer"},{"key":"6913_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi, S. S. & Badgwell, B. D. Current treatment and recent progress in gastric cancer. CA Cancer J. Clin. 71, 264\u2013279 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"6913_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s12094-021-02760-0","volume":"24","author":"G Roviello","year":"2022","unstructured":"Roviello, G. et al. Current status and future perspectives in HER2 positive advanced gastric cancer. Clin. Transl Oncol. 24, 981\u2013996 (2022).","journal-title":"Clin. Transl Oncol."},{"key":"6913_CR5","doi-asserted-by":"publisher","first-page":"101889","DOI":"10.1016\/j.ctrv.2019.101889","volume":"79","author":"M Salati","year":"2019","unstructured":"Salati, M. et al. Gastric cancer: translating novels concepts into clinical practice. Cancer Treat. Rev. 79, 101889 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"6913_CR6","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27 Supplement 5","author":"E Smyth","year":"2016","unstructured":"Smyth, E. et al. (ed, C.) Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 Supplement 5 v38\u2013v49 (2016).","journal-title":"Ann. Oncol."},{"key":"6913_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research, Network","year":"2014","unstructured":"Cancer Genome Atlas Research, Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","journal-title":"Nature"},{"key":"6913_CR8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos, C. & Jimeno, A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19, 1523\u20131529 (2008).","journal-title":"Ann. Oncol."},{"key":"6913_CR9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem, E. et al. HER2 screening data from toga: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 18, 476\u2013484 (2015).","journal-title":"Gastric Cancer"},{"key":"6913_CR10","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1002\/ijc.26292","volume":"130","author":"TC Chua","year":"2012","unstructured":"Chua, T. C. & Merrett, N. D. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes\u2013a systematic review. Int. J. Cancer. 130, 2845\u20132856 (2012).","journal-title":"Int. J. Cancer"},{"key":"6913_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/jclinpath-2012-200774","volume":"65","author":"C Gomez-Martin","year":"2012","unstructured":"Gomez-Martin, C. et al. HER2\/neu testing for anti-HER2-based therapies in patients with unresectable and\/or metastatic gastric cancer. J. Clin. Pathol. 65, 751\u2013757 (2012).","journal-title":"J. Clin. Pathol."},{"key":"6913_CR12","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1093\/annonc\/mds104","volume":"23","author":"YY Janjigian","year":"2012","unstructured":"Janjigian, Y. Y. et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann. Oncol. 23, 2656\u20132662 (2012).","journal-title":"Ann. Oncol."},{"key":"6913_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/PAI.0b013e31821c821c","volume":"20","author":"PL Kunz","year":"2012","unstructured":"Kunz, P. L. et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl. Immunohistochem. Mol. Morphol. 20, 13\u201324 (2012).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"6913_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mdi064","volume":"16","author":"M Tanner","year":"2005","unstructured":"Tanner, M. et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase iialpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273\u2013278 (2005).","journal-title":"Ann. Oncol."},{"key":"6913_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s10620-005-9057-1","volume":"51","author":"DI Park","year":"2006","unstructured":"Park, D. I. et al. HER-2\/neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci. 51, 1371\u20131379 (2006).","journal-title":"Dig. Dis. Sci."},{"key":"6913_CR16","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.2010.33.6313","volume":"29","author":"MD Begnami","year":"2011","unstructured":"Begnami, M. D. et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J. Clin. Oncol. 29, 3030\u20133036 (2011).","journal-title":"J. Clin. Oncol."},{"key":"6913_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"6913_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2015.09.018","volume":"53","author":"SR Park","year":"2016","unstructured":"Park, S. R. et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of gastric cancer HER2 reassessment study 1 (GASTHER1). Eur. J. Cancer. 53, 42\u201350 (2016).","journal-title":"Eur. J. Cancer"},{"key":"6913_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10120-021-01182-9","volume":"24","author":"G Roviello","year":"2021","unstructured":"Roviello, G. et al. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? Gastric Cancer. 24, 765\u2013779 (2021).","journal-title":"Gastric Cancer"},{"key":"6913_CR20","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s10120-014-0394-7","volume":"18","author":"Y Nishida","year":"2015","unstructured":"Nishida, Y. et al. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity. Gastric Cancer. 18, 458\u2013466 (2015).","journal-title":"Gastric Cancer"},{"key":"6913_CR21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546\u20131558 (2013).","journal-title":"Science"},{"key":"6913_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10120-016-0599-z","volume":"20","author":"K Shoda","year":"2017","unstructured":"Shoda, K. et al. Monitoring the HER2 copy number status in Circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer. 20, 126\u2013135 (2017).","journal-title":"Gastric Cancer"},{"key":"6913_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabieres","year":"2016","unstructured":"Alix-Panabieres, C. & Pantel, K. Clinical applications of Circulating tumor cells and Circulating tumor DNA as liquid biopsy. Cancer Discov. 6, 479\u2013491 (2016).","journal-title":"Cancer Discov"},{"key":"6913_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bjc.2015.417","volume":"114","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. Dynamic monitoring of Circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br. J. Cancer. 114, 138\u2013145 (2016).","journal-title":"Br. J. Cancer"},{"key":"6913_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.gastro.2016.05.052","volume":"151","author":"S Nagrath","year":"2016","unstructured":"Nagrath, S., Jack, R. M., Sahai, V. & Simeone, D. M. Opportunities and challenges for pancreatic Circulating tumor cells. Gastroenterology 151, 412\u2013426 (2016).","journal-title":"Gastroenterology"},{"key":"6913_CR26","doi-asserted-by":"publisher","first-page":"e0227366","DOI":"10.1371\/journal.pone.0227366","volume":"14","author":"F Watanabe","year":"2019","unstructured":"Watanabe, F. et al. Longitudinal monitoring of KRAS-mutated Circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLOS ONE. 14, e0227366 (2019).","journal-title":"PLOS ONE"},{"key":"6913_CR27","doi-asserted-by":"publisher","first-page":"24398","DOI":"10.18632\/oncotarget.25309","volume":"9","author":"Y Takayama","year":"2018","unstructured":"Takayama, Y. et al. Monitoring Circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer. Oncotarget 9, 24398\u201324413 (2018).","journal-title":"Oncotarget"},{"key":"6913_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41419-022-05350-2","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers. Cell. Death Dis. 13, 903 (2022).","journal-title":"Cell. Death Dis."},{"key":"6913_CR29","doi-asserted-by":"crossref","unstructured":"Lin, P. P. & Aneuploid, C. T. C. and CEC. Diagnostics (Basel) 8, 2 (2018).","DOI":"10.3390\/diagnostics8020026"},{"key":"6913_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/2193-1801-2-386","volume":"2","author":"SW Luoh","year":"2013","unstructured":"Luoh, S. W. et al. HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression. Springerplus 2, 386 (2013).","journal-title":"Springerplus"},{"key":"6913_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbcan.2017.12.005","volume":"1869","author":"PP Praharaj","year":"2018","unstructured":"Praharaj, P. P., Bhutia, S. K., Nagrath, S., Bitting, R. L. & Deep, G. Circulating tumor cell-derived organoids: current challenges and promises in medical research and precision medicine. Biochim. Biophys. Acta Rev. Cancer. 1869, 117\u2013127 (2018).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"6913_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl. J. Med. 351, 781\u2013791 (2004).","journal-title":"N Engl. J. Med."},{"key":"6913_CR33","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/nature06385","volume":"450","author":"S Nagrath","year":"2007","unstructured":"Nagrath, S. et al. Isolation of rare Circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235\u20131239 (2007).","journal-title":"Nature"},{"key":"6913_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00280-021-04251-z","volume":"87","author":"D Matsushita","year":"2021","unstructured":"Matsushita, D. et al. Clinical significance of Circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer. Cancer Chemother. Pharmacol. 87, 789\u2013797 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"6913_CR35","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1111\/cas.14092","volume":"110","author":"K Onidani","year":"2019","unstructured":"Onidani, K. et al. Monitoring of cancer patients via next-generation sequencing of patient-derived Circulating tumor cells and tumor DNA. Cancer Sci. 110, 2590\u20132599 (2019).","journal-title":"Cancer Sci."},{"key":"6913_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/1479-5876-12-143","volume":"12","author":"M Watanabe","year":"2014","unstructured":"Watanabe, M. et al. A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood. J. Transl Med. 12, 143 (2014).","journal-title":"J. Transl Med."},{"key":"6913_CR37","doi-asserted-by":"publisher","first-page":"e0167064","DOI":"10.1371\/journal.pone.0167064","volume":"11","author":"D Bhagirath","year":"2016","unstructured":"Bhagirath, D. et al. Mutant PIK3CA induces EMT in a cell type specific manner. PLOS ONE. 11, e0167064 (2016).","journal-title":"PLOS ONE"},{"key":"6913_CR38","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/0008-5472.CAN-19-3922","volume":"81","author":"H Tomihara","year":"2021","unstructured":"Tomihara, H. et al. Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress. Cancer Res. 81, 332\u2013343 (2021).","journal-title":"Cancer Res."},{"key":"6913_CR39","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.4161\/cc.10.10.15703","volume":"10","author":"Z Jiang","year":"2011","unstructured":"Jiang, Z. et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell. Cycle. 10, 1563\u20131570 (2011).","journal-title":"Cell. Cycle"},{"key":"6913_CR40","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3892\/ijo.27.6.1677","volume":"27","author":"M Katoh","year":"2005","unstructured":"Katoh, M. Epithelial-mesenchymal transition in gastric cancer (Review). Int. J. Oncol. 27, 1677\u20131683 (2005).","journal-title":"Int. J. Oncol."},{"key":"6913_CR41","doi-asserted-by":"publisher","first-page":"155379","DOI":"10.1016\/j.phymed.2024.155379","volume":"128","author":"CD Mohan","year":"2024","unstructured":"Mohan, C. D. et al. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy. Phytomedicine 128, 155379 (2024).","journal-title":"Phytomedicine"},{"key":"6913_CR42","doi-asserted-by":"crossref","unstructured":"Habli, Z., AlChamaa, W., Saab, R., Kadara, H. & Khraiche, M. L. Circulating tumor cell detection technologies and clinical utility: challenges and opportunities. Cancers (Basel) 12, 1930 (2020).","DOI":"10.3390\/cancers12071930"},{"key":"6913_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-023-01715-z","volume":"22","author":"S Ma","year":"2023","unstructured":"Ma, S. et al. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol. Cancer. 22, 7 (2023).","journal-title":"Mol. Cancer"},{"key":"6913_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.21873\/anticanres.15499","volume":"42","author":"M Ikeda","year":"2022","unstructured":"Ikeda, M. et al. High-purity isolation for genotyping rare cancer cells from blood using a microfluidic chip cell sorter. Anticancer Res. 42, 407\u2013417 (2022).","journal-title":"Anticancer Res."},{"key":"6913_CR45","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Trastuzumab Deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat. Med. 30, 1933\u20131942 (2024).","journal-title":"Nat. Med."},{"key":"6913_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5306\/wjco.v5.i3.311","volume":"5","author":"C Moyret-Lalle","year":"2014","unstructured":"Moyret-Lalle, C., Ruiz, E. & Puisieux, A. Epithelial-mesenchymal transition transcription factors and mirnas: plastic surgeons of breast cancer. World J. Clin. Oncol. 5, 311\u2013322 (2014).","journal-title":"World J. Clin. Oncol."},{"key":"6913_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nature14897","volume":"525","author":"X Ye","year":"2015","unstructured":"Ye, X. et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256\u2013260 (2015).","journal-title":"Nature"},{"key":"6913_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349\u2013361 (2012).","journal-title":"Cell"},{"key":"6913_CR49","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/ncb3513","volume":"19","author":"AM Krebs","year":"2017","unstructured":"Krebs, A. M. et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell. Biol. 19, 518\u2013529 (2017).","journal-title":"Nat. Cell. Biol."},{"key":"6913_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell. Biol. 20, 69\u201384 (2019).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"6913_CR51","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1038\/onc.2015.489","volume":"35","author":"S Ingthorsson","year":"2016","unstructured":"Ingthorsson, S. et al. HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR. Oncogene 35, 4244\u20134255 (2016).","journal-title":"Oncogene"},{"key":"6913_CR52","doi-asserted-by":"publisher","first-page":"9141","DOI":"10.3748\/wjg.v22.i41.9141","volume":"22","author":"Y Choi","year":"2016","unstructured":"Choi, Y. et al. HER2-induced metastasis is mediated by AKT\/JNK\/EMT signaling pathway in gastric cancer. World J. Gastroenterol. 22, 9141\u20139153 (2016).","journal-title":"World J. Gastroenterol."},{"key":"6913_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat. Rev. Mol. Cell. Biol. 21, 341\u2013352 (2020).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"6913_CR54","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11523-017-0493-6","volume":"12","author":"Y Mishima","year":"2017","unstructured":"Mishima, Y. et al. Detection of HER2 amplification in Circulating tumor cells of HER2-negative gastric cancer patients. Target. Oncol. 12, 341\u2013351 (2017).","journal-title":"Target. Oncol."},{"key":"6913_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/1476-4598-13-143","volume":"13","author":"D Cretella","year":"2014","unstructured":"Cretella, D. et al. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Mol. Cancer. 13, 143 (2014).","journal-title":"Mol. Cancer"},{"key":"6913_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13058-019-1229-6","volume":"21","author":"AA Davis","year":"2019","unstructured":"Davis, A. A. et al. Association of a novel Circulating tumor DNA next-generating sequencing platform with Circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Breast Cancer Res. 21, 137 (2019).","journal-title":"Breast Cancer Res."},{"key":"6913_CR57","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ng.2983","volume":"46","author":"K Wang","year":"2014","unstructured":"Wang, K. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573\u2013582 (2014).","journal-title":"Nat. Genet."},{"key":"6913_CR58","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06913-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06913-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06913-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:32:20Z","timestamp":1752139940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06913-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6913"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06913-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazuo Takeda are employees of On-chip Biotechnologies Co., Ltd., and Kazuo Takeda holds of stock of On-chip Biotechnologies Co., Ltd. The other authors have no conflicts of interest or financial ties related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"23906"}}